Want to see IN:GUJTHEM full AI Analyst Report?
GUJTHEM Stock Chart & Stats
₹432.00
--
Market closed
₹432.00
--
Day’s Range― - ―
52-Week Range₹225.75 - ₹479.45
Previous CloseN/A
VolumeN/A
Average Volume (3M)8.65K
Market Cap
₹40.22B
Enterprise Value₹42.95B
Total Cash (Recent Filing)₹103.83M
Total Debt (Recent Filing)₹714.92M
Price to Earnings (P/E)86.4
Beta1.98
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)2.41
Shares Outstanding108,965,260
10 Day Avg. Volume8,769
30 Day Avg. Volume8,646
Financial Highlights & Ratios
PEG Ratio-11.90
Price to Book (P/B)8.62
Price to Sales (P/S)14.96
P/FCF Ratio-19.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.9
Revenue Forecast (FY)₹1.88B
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthA ~107% revenue surge reflects meaningful demand expansion and larger scale in core API/intermediate sales. Over 2-6 months this scale supports stronger contract negotiating power, spreads fixed costs, and creates a platform to convert incremental revenue into durable earnings if maintained.
Strong Operating And Net MarginsHigh operating and net margins signal structural profitability from manufacturing efficiency or premium product mix. Such margin levels provide ongoing cash generation potential and buffer vs. input cost swings, supporting reinvestment or debt servicing if operational performance remains consistent.
B2B API Manufacturer With Domestic And Export ReachA focused API/intermediate manufacturing model serving both Indian formulators and export markets benefits from regulatory barriers, long product lifecycles and recurring customer demand. This structurally defensive B2B position supports steady revenue streams and repeat business over the medium term.
Bears Say
Rising LeverageA rapid increase in leverage materially raises financial risk and reduces flexibility to fund operations or counter downturns. Higher debt servicing needs can constrain capital allocation, increase vulnerability to cash shortfalls, and limit the company's ability to invest in capacity or new product lines over the next several quarters.
Weak Cash Generation / Negative Free Cash FlowSharp deterioration in operating cash and persistently negative free cash flow indicates earnings are less supported by cash. This structural cash gap may force external financing, restrict reinvestment, and heighten refinancing risk given the higher leverage unless operating cash conversion improves sustainably.
Material Gross Margin CompressionA large gross margin decline suggests adverse product mix, higher input costs, or pricing pressure. If persistent, this compresses the fundamental profitability cushion, making the business more sensitive to cost volatility and undermining the durability of operating margins despite revenue growth.
Gujarat Themis Biosyn Ltd News
GUJTHEM FAQ
What was Gujarat Themis Biosyn Ltd’s price range in the past 12 months?
Gujarat Themis Biosyn Ltd lowest stock price was ₹225.75 and its highest was ₹479.45 in the past 12 months.
What is Gujarat Themis Biosyn Ltd’s market cap?
Gujarat Themis Biosyn Ltd’s market cap is ₹40.22B.
When is Gujarat Themis Biosyn Ltd’s upcoming earnings report date?
Gujarat Themis Biosyn Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Gujarat Themis Biosyn Ltd’s earnings last quarter?
Gujarat Themis Biosyn Ltd released its earnings results on May 25, 2026. The company reported ₹1 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.
Is Gujarat Themis Biosyn Ltd overvalued?
According to Wall Street analysts Gujarat Themis Biosyn Ltd’s price is currently Overvalued.
Does Gujarat Themis Biosyn Ltd pay dividends?
Gujarat Themis Biosyn Ltd pays a Notavailable dividend of ₹0.67 which represents an annual dividend yield of 0.16%. See more information on Gujarat Themis Biosyn Ltd dividends here
What is Gujarat Themis Biosyn Ltd’s EPS estimate?
Gujarat Themis Biosyn Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gujarat Themis Biosyn Ltd have?
Gujarat Themis Biosyn Ltd has 108,965,260 shares outstanding.
What happened to Gujarat Themis Biosyn Ltd’s price movement after its last earnings report?
Gujarat Themis Biosyn Ltd reported an EPS of ₹1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.988%.
Which hedge fund is a major shareholder of Gujarat Themis Biosyn Ltd?
Currently, no hedge funds are holding shares in IN:GUJTHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd. is an Indian company primarily involved in the creation of pharmaceuticals and medicinal chemicals. The firm also supplies bulk drugs via a job work model within India. Its product offerings include important compounds such as Rifamycin-S, an intermediate used in treatments for tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease. Another key product, Rifamycin-O, addresses ailments like traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy. Furthermore, they produce Lovastatin. Established in 1981, the company's operations are based out of Mumbai, India.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Gufic Biosciences Limited
―
Orchid Pharma Limited
―
RPG Life Sciences Limited
―
Zota Health Care Ltd.
―